With hit-and-miss da­ta, Al­lakos goes the pub­lic of­fer­ing route in $150M ask

Cal­i­for­nia-based biotech Al­lakos, which works on al­ler­gies and in­flam­ma­tion-re­lat­ed dis­eases, is mak­ing hay while the sun shines.

Ten days af­ter an­nounc­ing luke­warm re­sults of its lead drug can­di­date, the com­pa­ny an­nounced it was seek­ing $150 mil­lion via an un­der­writ­ten of­fer­ing of shares of its com­mon stock $AL­LK.

The com­pa­ny’s 24-week da­ta from its Phase III tri­al EoDyssey was in­ves­ti­gat­ing its lead drug can­di­date lirente­limab in pa­tients with con­firmed eosinophilic duo­deni­tis — a chron­ic in­flam­ma­to­ry dis­ease char­ac­ter­ized by in­flam­ma­tion in the stom­ach and part of the small in­tes­tine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER